市場調查報告書
商品編碼
817637

癌症治療用遺傳基因醫學的全球市場 - 市場佔有率,市場規模,趨勢,產業分析,及未來預測

Genomics in Cancer Care Market Share, Size, Trends, & Industry Analysis Report, By Product type; By Technology, By Application; By End Use; and By Region: Segment Forecast, 2019 - 2025

出版日期: | 出版商: Polaris Market Research | 英文 113 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告涵括癌症治療用遺傳基因醫學的全球市場,基於市場規模,成長促進因素及阻礙因素,市場機會,產業趨勢,以及市場競爭情形等廣泛調查,來進行市場現狀分析以及未來預測。同時更提供各產品類型,各技術類型,各用途,各終端用戶,及各地區類別之市場詳細分析與預測。

第1章 市場概要及範圍

  • 調查目的及調查範圍
  • 調查上的估計條件
  • 調查手法
  • 本調查的成果
  • 利害關係者

第2章 摘要整理

  • 市場定義
  • 市場分類

第3章 癌症治療用遺傳基因醫學市場預測

  • 癌症治療用遺傳基因醫學 - 產業概況
    • 主要企業
    • 關注企業
  • 癌症治療用遺傳基因醫學 - 生態系統分析
    • 疾病概要
    • 商業性現狀
  • 癌症治療用遺傳基因醫學市場動態
    • 癌症治療用遺傳基因醫學 - 市場影響要素
  • 產業分析 - 波特的五力分析
  • 癌症治療用遺傳基因醫學市場PEST分析
  • 癌症治療用遺傳基因醫學市場價值鏈分析
  • 癌症治療用遺傳基因醫學產業趨勢
  • 競爭力排行榜分析

第4章 癌症治療用遺傳基因醫學市場各產品類型市場規模及未來預測

  • 重要的調查結果
  • 消耗品
  • 器具類
  • 服務

第5章 癌症治療用遺傳基因醫學市場各技術類型市場規模及未來預測

  • 重要的調查結果
  • 基因譯解
  • PCR (聚合酵素鏈鎖反應)
  • 微陣列核酸提取及煉製

第6章 癌症治療用遺傳基因醫學市場各用途市場規模及未來預測

  • 診斷
  • 定做醫療
  • 藥物輸送
  • 研究

第7章 癌症治療用遺傳基因醫學市場各終端用戶市場規模及未來預測

  • 醫院
  • 研究所
  • 學術研究機關

第8章 癌症治療用遺傳基因醫學市場各地區市場規模及未來預測

  • 重要的調查結果
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 比利時
    • 俄羅斯
    • 荷蘭
    • 其他的歐洲各國
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 新加坡
    • 馬來西亞
    • 印尼
    • 泰國
    • 菲律賓
    • 其他的亞太地區各國
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他的南美各國
  • 中東及非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他的中東·非洲各國

第9章 企業簡介

  • Aligent Technologies
  • Roche Diagnostics
  • Beckman Coulter
  • Illumina, Inc.
  • Affymetric
  • Cancer Genetic Inc.
  • Bio-rad Labs
  • Pacific Bio-Sciences
  • Sigma Aldrich Corporation
  • GE Healthcare
  • Quest Diagnostics
  • Abbott Laboratories
  • PerkinElmer
  • Luminex
目錄
Product Code: PM1607

The global genomics in cancer care market size is anticipated to reach USD 14.6 billion by 2025 growing at a CAGR of 17.7% from 2019 to 2025 according to a new report published by Polaris Market Research. The report 'Genomics in Cancer Care Market Share, Size, Trends, & Industry Analysis Report, By Product type (Consumables, Instruments, Services); By Technology, By Application; By End Use; and By Region: Segment Forecast, 2019 - 2025' provides insights on the current market scenario and the future prospects.

In 2018, by product type, instrument segment captures the largest market shares in terms of revenue and hold major share in the market. Regionally, North America accounted for the major share in the global market.

The market is primarily driven by increasing prevalence of cancer patients globally, and rising demand for diagnostic coupled with the availability of cost effective and technologically advanced technology. Additionally, awareness and growing preference for personalized medicines is also influencing the market growth. Moreover, continuous investment on research and developments by the biotechnology & pharmaceutical companies would also fuel the market growth.

Product segment is further sub-segmented into consumables and reagents, instruments, and services. Instruments market holds the major share in the market owning to the rapid technological advancements, and continuous efforts by the manufacturers for providing digitalization in the instruments for its easy use. While consumables and reagents hold second largest position for market followed by the service sub segment.

Based on technology, the market is segmented as genome sequencing, PCR, microarray nucleic acid extraction and purification. Genome sequencing holds the major market share in 2017, and would continue to experience growth during the forecast period. The growth in this segment is majorly driven by the effective and precise diagnosis results, and rising awareness for its use in cancer diagnosis. Moreover, advantages like growing demand for cost-effective technologies, and flexibility in this technique would also influence the growth of genome sequencing market.

On the basis of application, the market is further segmented as diagnostics, personalized medicines, drug discovery, and Research. This application is majorly used for diagnosis of cancer. Diagnostics holds the largest market share which is majorly attributed to the growing number of cancer patients worldwide.

Research institute is the largest segment as an end user for the market, and would hold dominating position during the forecast period. The growth of genomics market in cancer care is primarily driven by the need for accurate screening techniques that gives to the point diagnosis of cancer.

Geographically, North America holds a dominating position in the global genomics in cancer care market followed by Europe and Asia Pacific. The market growth in North America is driven by the presence of refined research & development infrastructure for the researchers, large pool of patients suffering from cancer, and high healthcare expenditure by the individuals. Whereas, Asia Pacific is expected to reach remarkable growth owning to the increased penetration rate of these technologies and improving research and development expenditure by the biopharma industries.

The leading companies operating in this industry include Agilent Technologies, Roche Diagnostics, Beckman Coulter, Illumina, Inc., Affymetrix, Cancer Genetic Inc., Bio-Rad Labs, Pacific Bio-science, Sigma Aldrich Corporation, GE Healthcare, Quest Diagnostics, Abbott Laboratories, PerkinElmer, and Luminex.

Key Findings from the study suggest technology available in the market are continuously concentrating on the technological advancements that will reduce the efforts and provide with accurate diagnosis of cancer. The leading companies while developing new technologies considers the factors such as increasing awareness for the use of this technology, and reaching the untapped market. North America is presumed to dominate the global market over the forecast years and Asia Pacific region shows signs of high growth owing to the booming economies of India, and China.

Polaris Market Research has segmented the genomics in cancer care market on the basis of product type, technology, application, end user and region:

Genomics in Cancer Care Product Type Outlook (Revenue, USD Million, 2015 - 2025)

Consumables

Instruments

Service

Genomics in Cancer Care Technology Type Outlook (Revenue, USD Million, 2015 - 2025)

Gene Sequencing

PCR

Microarray Nucleic Acid Extraction and Purification

Genomics in Cancer Care Application Outlook (Revenue, USD Million, 2015 - 2025)

Diagnostics

Personalized Medicines

Drug Delivery

Research

Genomics in Cancer Care Product End Use Outlook (Revenue, USD Million, 2015 - 2025)

Hospitals

Research Institutes

Academic Research

Genomics in Cancer Care Product Regional Outlook (Revenue, USD Million, 2015 - 2025)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Belgium

Russia

Netherlands

Rest of Europe

Asia-Pacific

China

India

Japan

Korea

Singapore

Malaysia

Indonesia

Thailand

Philippines

Rest of Asia-Pacific

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

Middle East & Africa

UAE

Saudi Arabia

South Africa

Rest of MEA

Table of Contents

1. Overview and Scope

  • 1.1. Research goal & scope
  • 1.2. Research assumptions
  • 1.3. Research methodology
    • 1.3.1. Primary data sources
    • 1.3.2. Secondary data sources
  • 1.4. Key take-away
  • 1.5. Stakeholders

2. Executive Summary

  • 2.1. Market definition
  • 2.2. Market segmentation

3. Genomics in Cancer Care Market Insights

  • 3.1. Genomics in Cancer Care - Industry snapshot
    • 3.1.1. Leading Companies
    • 3.1.2. Key Companies to Watch
  • 3.2. Genomics in Cancer Care - Ecosystem analysis
    • 3.2.1. Disease overview
    • 3.2.2. Commercial Landscape
  • 3.3. Genomics in Cancer Care Market Dynamics
    • 3.3.1. Genomics in Cancer Care - Market Forces
      • 3.3.1.1. Genomics in Cancer Care Market Driver Analysis
      • 3.3.1.2. Genomics in Cancer Care Market Restraint/Challenges analysis
      • 3.3.1.3. Genomics in Cancer Care Market Opportunity Analysis
  • 3.4. Industry analysis - Porter's five forces
    • 3.4.1. Bargaining power of supplier
    • 3.4.2. Bargaining power of buyer
    • 3.4.3. Threat of substitute
    • 3.4.4. Threat of new entrant
    • 3.4.5. Degree of competition
  • 3.5. Genomics in Cancer Care Market PEST Analysis
  • 3.6. Genomics in Cancer Care Market Value Chain Analysis
  • 3.7. Genomics in Cancer Care Industry Trends
  • 3.8. Competitive Ranking Analysis, 2018

4. Genomics in Cancer Care Market Size and Forecast, by Product Types

  • 4.1. Key Findings
  • 4.2. Consumables
  • 4.3. Instruments
  • 4.4. Service

5. Genomics in Cancer Care Market Size and Forecast, by Technology Type

  • 5.1. Key Findings
  • 5.2. Genome Sequencing
  • 5.3. PCR
  • 5.4. Microarray Nucleic Acid Extraction & Purification

6. Genomics in Cancer Care Market Size and Forecast, by Application

  • 6.1. Diagnostics
  • 6.2. Personalized Medicines
  • 6.3. Drug Delivery
  • 6.4. Research

7. Genomics in Cancer Care Market Size and Forecast, by End Use

  • 7.1. Hospitals
  • 7.2. Research Institutes
  • 7.3. Academic Research Institutes

8. Genomics in Cancer Care Market Size and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. Germany
    • 8.3.2. UK
    • 8.3.3. France
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Belgium
    • 8.3.7. Russia
    • 8.3.8. Netherlands
    • 8.3.9. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. China
    • 8.4.2. India
    • 8.4.3. Japan
    • 8.4.4. Korea
    • 8.4.5. Singapore
    • 8.4.6. Malaysia
    • 8.4.7. Indonesia
    • 8.4.8. Thailand
    • 8.4.9. Philippines
    • 8.4.10. Rest of Asia-Pacific
  • 8.5. Latin America
    • 8.5.1. Brazil
    • 8.5.2. Mexico
    • 8.5.3. Argentina
    • 8.5.4. Rest of LATAM
  • 8.6. Middle East & Africa
    • 8.6.1. UAE
    • 8.6.2. Saudi Arabia
    • 8.6.3. South Africa
    • 8.6.4. Rest of MEA

9. Company Profiles

  • 9.1. Aligent Technologies
    • 9.1.1. Overview
    • 9.1.2. Financials
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Developments
  • 9.2. Roche Diagnostics
    • 9.2.1. Overview
    • 9.2.2. Financials
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Developments
  • 9.3. Beckman Coulter
    • 9.3.1. Overview
    • 9.3.2. Financials
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Developments
  • 9.4. Illumina, Inc.
    • 9.4.1. Overview
    • 9.4.2. Financials
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Developments
  • 9.5. Affymetric
    • 9.5.1. Overview
    • 9.5.2. Financials
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Developments
  • 9.6. Cancer Genetic Inc.
    • 9.6.1. Overview
    • 9.6.2. Financials
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Developments
  • 9.7. Bio-rad Labs
    • 9.7.1. Overview
    • 9.7.2. Financials
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Developments
  • 9.8. Pacific Bio-Sciences
    • 9.8.1. Overview
    • 9.8.2. Financials
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Developments
  • 9.9. Sigma Aldrich Corporation
    • 9.9.1. Overview
    • 9.9.2. Financials
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Developments
  • 9.10. GE Healthcare
    • 9.10.1. Overview
    • 9.10.2. Financials
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Developments
  • 9.11. Quest Diagnostics
    • 9.11.1. Overview
    • 9.11.2. Financials
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Developments
  • 9.12. Abbott Laboratories
    • 9.12.1. Overview
    • 9.12.2. Financials
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Developments
  • 9.13. PerkinElmer
    • 9.13.1. Overview
    • 9.13.2. Financials
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Developments
  • 9.14. Luminex
    • 9.14.1. Overview
    • 9.14.2. Financials
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Developments